Zobrazeno 1 - 10
of 771
pro vyhledávání: '"J.P. Kastelein"'
Autor:
Nehal Mehta, Katerina Dangas, Marc Ditmarsch, Patrick C.N. Rensen, Mary R. Dicklin, John J.P. Kastelein
Publikováno v:
Pharmacological Research, Vol 197, Iss , Pp 106972- (2023)
The main role of cholesteryl ester transfer protein (CETP) is the transfer of cholesteryl esters and triglycerides between high-density lipoprotein (HDL) particles and triglyceride-rich lipoprotein and low-density lipoprotein (LDL) particles. There i
Externí odkaz:
https://doaj.org/article/918b765963b84cddbb82eae8be499d93
Autor:
Daniel Gaudet, Andrea Ruzza, Ian Bridges, Paul Maruff, Adrian Schembri, Andrew Hamer, François Mach, Jean Bergeron, Isabelle Gaudet, Julie St Pierre, John J.P. Kastelein, G. Kees Hovingh, Albert Wiegman, Frederick J. Raal, Raul D. Santos
Publikováno v:
Journal of clinical lipidology, 16(5), 676-684. Elsevier BV
Gaudet, D, Ruzza, A, Bridges, I, Maruff, P, Schembri, A, Hamer, A, Mach, F, Bergeron, J, Gaudet, I, Pierre, J S, Kastelein, J J P, Hovingh, G K, Wiegman, A, Raal, F J & Santos, R D 2022, ' Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia ', Journal of clinical lipidology, vol. 16, no. 5, pp. 676-684 . https://doi.org/10.1016/j.jacl.2022.07.005
Gaudet, D, Ruzza, A, Bridges, I, Maruff, P, Schembri, A, Hamer, A, Mach, F, Bergeron, J, Gaudet, I, Pierre, J S, Kastelein, J J P, Hovingh, G K, Wiegman, A, Raal, F J & Santos, R D 2022, ' Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia ', Journal of clinical lipidology, vol. 16, no. 5, pp. 676-684 . https://doi.org/10.1016/j.jacl.2022.07.005
Background: Evolocumab is a fully human monoclonal antibody inhibitor of PCSK9 approved for lowering low-density lipoprotein cholesterol in adults and pediatric patients with familial hypercholesterolemia (FH). The cognitive safety of evolocumab has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53bd095a1e523ff9cb790c1a2f4617c7
http://www.scopus.com/inward/record.url?scp=85139726527&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85139726527&partnerID=8YFLogxK
Autor:
Lotte M. de Boer, Michel H. Hof, Albert Wiegman, An K. Stroobants, John J.P. Kastelein, Barbara A. Hutten
Publikováno v:
Atherosclerosis, 349, 227-232. Elsevier Ireland Ltd
Background and aims: Elevated lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease. In clinical practice, Lp(a) is mostly measured only once assuming that it does not change with age nor vary within individuals. This is mai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a71162ba6bb1e63b0f4d8535084a5b6f
https://doi.org/10.1016/j.atherosclerosis.2022.03.004
https://doi.org/10.1016/j.atherosclerosis.2022.03.004
Publikováno v:
de Boer, L M, Wiegman, A, Swerdlow, D I, Kastelein, J J P & Hutten, B A 2022, ' Pharmacotherapy for children with elevated levels of lipoprotein(a) : future directions ', Expert Opinion on Pharmacotherapy, vol. 23, no. 14, pp. 1601-1615 . https://doi.org/10.1080/14656566.2022.2118522
Introduction: Elevated lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). With the advent of the antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) targeted at LPA, that are hig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96214fe900c7ceb18b02b283cbe42b8c
https://doi.org/10.1080/14656566.2022.2118522
https://doi.org/10.1080/14656566.2022.2118522
Autor:
Arjen J. Cupido, Michel H. Hof, Lotte M. de Boer, Roeland Huijgen, Erik S.G. Stroes, John J.P. Kastelein, G. Kees Hovingh, Barbara A. Hutten
Publikováno v:
Journal of clinical lipidology. Elsevier BV
Background: Statins are the primary therapy in patient with heterozygous familial hypercholesterolemia (HeFH). Non-adherence to statin therapy is associated with increased cardiovascular risk. Objective: We constructed a dynamic prediction model to p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::653db10c28903709535fde223bf0db07
https://doi.org/10.1016/j.jacl.2022.12.004
https://doi.org/10.1016/j.jacl.2022.12.004
Autor:
Deepak L. Bhatt, Harold E. Bays, Michael Miller, Teresa Parli, Shibao Feng, Lulu Sterling, Cynthia L. Hartsfield, Germaine D. Agollah, Hank Mansbach, John J.P. Kastelein
Publikováno v:
Metabolism. 142:155456
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e91681990724e12d66999707be6db955
https://doi.org/10.1016/j.metabol.2023.155456
https://doi.org/10.1016/j.metabol.2023.155456
Publikováno v:
Expert review of molecular diagnostics. 21(9):887-895
Introduction: Familial hypercholesterolemia (FH) is a highly prevalent condition, predisposing individuals to premature cardiovascular disease and with a genetic basis more complex than initially thought. Advances in molecular technologies have provi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c53463bef7f78d0fb23251fd41c9cfd
http://www.scopus.com/inward/record.url?scp=85111077619&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85111077619&partnerID=8YFLogxK
Autor:
David A. Fraser, Xiaoyu Wang, Jenny Lund, Nataša Nikolić, Marta Iruarrizaga-Lejarreta, Tore Skjaeret, Cristina Alonso, John J.P. Kastelein, Arild C. Rustan, Yong Ook Kim, Detlef Schuppan
Publikováno v:
Journal of hepatology, 76(4), 800-811. Elsevier
Background & Aims: Although long-chain omega-3 fatty acids (LCn-3FAs) regulate inflammatory pathways of relevance to non-alcoholic steatohepatitis (NASH), their susceptibility to peroxidation may limit their therapeutic potential. We compared the met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24bb34640194cc100454542ea670cf9b
https://pure.amc.nl/en/publications/a-structurally-engineered-fatty-acid-icosabutate-suppresses-liver-inflammation-and-fibrosis-in-nash(f9db8dc2-fa29-42cc-b2b8-ea1f1a47881f).html
https://pure.amc.nl/en/publications/a-structurally-engineered-fatty-acid-icosabutate-suppresses-liver-inflammation-and-fibrosis-in-nash(f9db8dc2-fa29-42cc-b2b8-ea1f1a47881f).html
Autor:
Adriaan G. Holleboom, Lily Jakulj, Remco Franssen, Julie Decaris, Menno Vergeer, Joris Koetsveld, Jayraz Luchoomun, Alexander Glass, Marc K. Hellerstein, John J.P. Kastelein, G. Kees Hovingh, Jan Albert Kuivenhoven, Albert K. Groen, Scott M. Turner, Erik S.G. Stroes
Publikováno v:
Journal of Lipid Research, Vol 54, Iss 7, Pp 1964-1971 (2013)
Atheroprotection by high density lipoprotein (HDL) is considered to be mediated through reverse cholesterol transport (RCT) from peripheral tissues. We investigated in vivo cholesterol fluxes through the RCT pathway in patients with low plasma high d
Externí odkaz:
https://doaj.org/article/eb57f8d7a91447d3adb89517819b0787
Autor:
Patrick C.N. Rensen, Geurt Stokman, Hans M.G. Princen, Michael Feigh, Marta Iruarrizaga-Lejarreta, José W.A. van der Hoorn, Ditte Denker Thorbekk, John J.P. Kastelein, Sanne Skovgård Veidal, Elsbet J. Pieterman, Lars Verschuren, David A. Fraser, Cristina Alonso, Scott L. Friedman, Brittany Basta, Tore Skjaeret, Anita M. van den Hoek, Jimmy F.P. Berbée
Publikováno v:
Liver International
Liver International, 40(11), 2860-2876. WILEY
Liver International, 40(11), 2860-2876. WILEY
Background & Aims While fibrosis stage predicts liver‐associated mortality, cardiovascular disease (CVD) is still the major overall cause of mortality in patients with NASH. Novel NASH drugs should thus ideally reduce both liver fibrosis and CVD. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5dde65642a000592115aac1140f902d
https://doi.org/10.1111/liv.14643
https://doi.org/10.1111/liv.14643